US 12,448,445 B2
Transgene genetic tags and methods of use
Michael C. Jensen, Bainbridge Island, WA (US); and Adam Johnson, Seattle, WA (US)
Assigned to Seattle Children's Hospital, Seattle, WA (US)
Filed by Seattle Children's Hospital, Seattle, WA (US)
Filed on Jul. 15, 2022, as Appl. No. 17/812,848.
Application 16/794,673 is a division of application No. 15/302,420, granted, now 10,611,837, previously published as PCT/US2015/024895, filed on Apr. 8, 2015.
Application 17/812,848 is a continuation of application No. 16/794,673, filed on Feb. 19, 2020, granted, now 11,414,486.
Claims priority of provisional application 62/090,845, filed on Dec. 11, 2014.
Claims priority of provisional application 62/089,730, filed on Dec. 9, 2014.
Claims priority of provisional application 62/088,363, filed on Dec. 5, 2014.
Claims priority of provisional application 62/058,973, filed on Oct. 2, 2014.
Claims priority of provisional application 61/986,479, filed on Apr. 30, 2014.
Claims priority of provisional application 61/977,751, filed on Apr. 10, 2014.
Prior Publication US 2022/0380461 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2025.01); A61K 35/28 (2015.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 9/12 (2006.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); G01N 33/577 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 35/28 (2013.01); A61K 38/1774 (2013.01); A61K 38/179 (2013.01); A61K 38/1793 (2013.01); A61K 39/3955 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C07K 14/7151 (2013.01); C07K 16/2818 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/12 (2013.01); C12N 15/85 (2013.01); C12Y 207/10001 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/14 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 15/62 (2013.01); C12N 2510/00 (2013.01); C12N 2800/90 (2013.01); G01N 33/68 (2013.01)] 17 Claims
 
1. A method for enriching a population of cells for expression of a truncated HER2 polypeptide, the method comprising:
(a) introducing into a population of isolated cells a nucleic acid to obtain a population of transduced cells, wherein the nucleic acid encodes a truncated HER2 polypeptide comprising an HER2 extracellular domain linked via a spacer to a transmembrane domain, wherein the extracellular domain comprises a sequence having at least 95% identity to amino acids 563 to 652 of SEQ ID NO:23, wherein the spacer comprises an IgG4 hinge domain or the amino acid sequence of SEQ ID NO:45, wherein the truncated HER2 polypeptide excludes the full length mature HER2; and
(b) isolating a population of cells expressing the truncated HER2 polypeptide from the population of transduced cells of step (a).